Neurotrophic Receptor Tyrosine Kinase 3 (NTRK3) Gene Mutation Analysis (Translocation)
The NTRK3 gene, located on chromosome 15q25.3, encodes a member of the neurotrophic receptor tyrosine kinase (NTRK) family known as TrkC, which binds to neurotrophin-3 (NT-3). Upon ligand binding, TrkC activates downstream signaling cascades such as the MAPK/ERK, PI3K/AKT, and PLCγ pathways, which are essential for neuronal survival, differentiation, and maintenance.
In oncogenesis, chromosomal rearrangements or fusions involving NTRK3 result in constitutive activation of the kinase domain, leading to uncontrolled cellular proliferation and survival. These fusions act as oncogenic drivers in various tumors, including secretory carcinoma of the breast, congenital fibrosarcoma, gliomas, and thyroid and salivary gland carcinomas.
Detection of NTRK3 fusions or mutations assists in selecting patients eligible for TRK inhibitor therapies such as larotrectinib (Vitrakvi®) and entrectinib (Rozlytrek®), which have shown durable responses across multiple tumor types harboring NTRK fusions.
- Assists in diagnosing and characterizing tumors with NTRK3 gene alterations
- Identifies patients eligible for TRK inhibitor therapy (e.g., larotrectinib, entrectinib)
- Provides molecular prognostic information in cancers such as breast, thyroid, and gliomas
Positive: Presence of NTRK3 gene rearrangement or translocation detected, consistent with tumors that may respond to TRK inhibitor therapy.
Negative: No mutation or translocation detected in the NTRK3 gene. However, a negative result does not exclude the presence of low-level variants or fusions not covered by the assay.
Results should be interpreted in conjunction with clinical findings, histopathologic evaluation, and other molecular studies.
Negative (No mutation or fusion detected).
Whole blood, EDTA.
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen: Unstable
- J Med Sci. 2024 May;40(5):445-455. [PMID: 38593276]
- Int J Surg Pathol. 2025 Feb;33(1):204-208. [PMID: 38772598]
- J Neurosurg Case Lessons. 2022 Jan 31;3(5):CASE21645. [PMID: 36130567]
- Oncologist. 2021 Oct;26(10):818-824. [PMID: 34176200]
- Mod Pathol. 2020 Jul;33(7):1341-1349. [PMID: 32034283]